Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBT-NM108 for Early Symptomatic COVID-19
NCT04540406Phase 2Completed
- Sponsor
- Notitia Biotechnologies
- Start
- Nov 2021
- Primary completion
- Mar 2022
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NBT-NM108 in coronavirus disease 2019 (COVID-19), sponsored by Notitia Biotechnologies. Started Nov 2021; status: completed.
02
Drugs
NBT-NM108
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04540406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540406.